A Phase 3 interventional study of Kedrion IVIG 10% in Primary Immunodeficiency Disease, sponsored by Kedrion S.p.A.. Completed at 11 sites in United States. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 12th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2019, is one of 18 in phase 3, and was the 22nd registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
Kedrion S.p.A. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Kedrion S.p.A. has 3 studies filed under Primary Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligrams per kilogram (mg/kg) body weight on every 21 or 28 days for period of 48 weeks.
Biological: Kedrion IVIG 10%
Kedrion intravenous immunoglobulin (IVIg) 10%
Incidence Rate of Acute Serious Bacterial Infections (ABSIs)
Incidence rate was defined as the mean number of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year according to pre-specified criteria.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Serum Immunoglobulin G (IgG) Trough Levels
The serum IgG trough levels were collected and analyzed at a central laboratory.
Time frame: At baseline, Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Immunoglobulin G (IgG) Subclasses Levels (IgG1, IgG2, IgG3, IgG4)
IgG subclasses levels (IgG1, IgG2, IgG3, IgG4) were collected and analyzed at a central laboratory.
Time frame: At baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Number of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria
Number of participants with Total IgG trough levels \<= 6 g/L criteria were reported.
Time frame: Up to 12 months
Anti-Tetanus Toxoid Antibody Levels
The anti-tetanus toxoid antibody levels were collected and analyzed at a central laboratory. This antibody level was measured in international units per milliliter (IU/mL).
Time frame: Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Anti-Pneumococcal Capsular Polysaccharide Antibody Levels
Anti-pneumococcal capsular polysaccharide antibody levels for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 were collected and analyzed at a central laboratory.
Time frame: Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Anti-Measles Antibody Levels
The anti-measles antibody levels were collected and analyzed at a central laboratory.
Time frame: Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Anti-Haemophilus Influenza Type B Antibody Levels
The anti-haemophilus influenza type B antibody levels were collected and analyzed at central laboratory.
Time frame: Baseline, Weeks 16, 32 and 48 (28 -day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Incidence Rate of Any Infection Other Than Acute Serious Bacterial Infections
Incidence rate was defined as the mean number of any infection other than acute serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year. Incidence rate of any infection other than acute bacterial serious infections collected by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Duration of Any Infection Other Than Acute Serious Bacterial Infections
Duration of any infection other than serious acute bacterial infections (in days) was calculated as date of stop of infection - date of start of infection + 1. Duration of any infection other than serious acute bacterial infections collected by the by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Incidence Rate of Fever Episodes
Incidence rate was defined as the mean number of fever episodes per participant-year. Incidence rate of fever episodes collected by the participant/participant's parent(s)/legal guardian(s) in the participant diary or during clinic visit were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Duration of Fever Episodes in Participants
Duration of fever episodes in participants was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Duration of Overall Participants Hospitalization
Duration of overall participants hospitalization was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Duration of Participants Hospitalization Due to Infection
Duration of participants hospitalization due to infection was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Incidence Rate of Antibiotics Episodes for Treatment of Any Kind of Infections
Incidence rate was defined as the mean number of antibiotics episodes per participant year. Incidence rate of participants on antibiotics for treatment of any kind of infections was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Duration of Participants on Antibiotics for Treatment of Any Kind of Infection
Duration of participants on antibiotics for treatment of any kind of infection was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Duration of Missed School/Work/Other Major Activities Due to Infections
Duration of missed school/work/other major activities due to infections was reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Pediatric Quality of Life Inventory (PedsQL) Score
23-item PedsQL generic core scales was a modular approach to measure health-related Quality of Life (QoL) in healthy children, adolescents and those with acute and chronic health conditions. The total scale score (23 items) consisted of Physical Health Summary Score (8 items) and Psychosocial Health SummaryScore (15 items). Physical health summary included Physical Functioning (8 items) and Psychosocial health summary score included Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale, where higher scores indicated better QoL. The overall range for total PedsQL score (23 items) was 0 to 100, with higher score indicated better QoL. Data for 18-25 years and \>25 years age group was reported.
Time frame: Baseline, Week 24 (21-day dosing schedule and 28-day dosing schedule), Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAE was defined as an AE with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious TEAEs.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of TEAEs and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A SAE was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. A TEAE was defined as an AE with an onset that occurs after receiving study drug. Number of TEAEs and Serious TEAEs were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Drug Related Infusion Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. Number of drug related infusion AEs were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Percentage of Participants Who Experienced at Least One Drug Related Infusion Adverse Events (AEs)
Percentage of participants who experienced at least one drug related infusion AEs were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Infusions With Decreased Infusion Rate Due to Adverse Events (AEs)
Number of infusions with decreased infusion rate due to AEs were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Infusions With One or More Infusion Associated Adverse Events (AEs)
The number of infusions with one or more infusion associated AEs were reported collectively for 21 and 28-day dosing schedule up to Week 52.
Time frame: Baseline up to Week 52
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Vital signs included body temperature, systolic and diastolic blood pressure, heart rate and weight. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Participants With Clinically Significant Changes From Baseline in Physical Examinations
Physical examination included the examination of general appearance, skin, neck, eyes, ears, nose, throat, cardiovascular assessment including rhythm, and presence of other cardiac abnormalities (for example gallops, murmurs, cardiomegaly), respiratory system, gastrointestinal system, genitourinary system and musculoskeletal system. Clinical significance was decided by the investigator. The number of participants with clinically significant changes from baseline in physical examination were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
Laboratory parameters included chemistry, hematology and urinalysis. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Number of Participants With Positive Coomb's Test at Week 16 (28-day Dosing Schedule) and Week 18 (21-day Dosing Schedule)
Intravascular hemolysis testing was performed by using coomb's test. The coomb's assessment was performed at a central laboratory.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Number of Participants With Positive Urine Hemosiderin Test
Number of participants with positive urine hemosiderin test were reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Number of Participants With Abnormal Plasma-free Haemoglobin Level
Number of participants with plasma-free haemoglobin level more than or equal to (\>=) 69 milligrams per deciliter (mg/dL) were consisdered as abormal and were reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Number of Participants With Abnormal Serum Haptoglobin Level
Number of participants with abnormal serum haptoglobin level were reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Maximum Observed Serum Concentration (Cmax) of Total Immunoglobulin G (IgG)
Cmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Half-Life (t1/2) of Total IgG
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Total IgG
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total IgG
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Total IgG
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Volume of Distribution (Vd) of Total IgG
Vd was defined as the the theoretical volume in which the total amount of total IgG would need to be uniformly distributed to produce the desired blood concentration of a total IgG. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Steady State Clearance (CLss) of Total IgG
Clearance of a total IgG was a measure of the rate at which a total IgG is metabolized or eliminated by normal biological processes. CLss of total IgG was measured in milliliters per hour per kilogram (mL/hr/kg). Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Minimum Observed Serum Concentration (Cmin) of Total IgG
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Time to Reach the Maximum Serum Concentration (Tmax) of Total IgG
Tmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Rate Constant (Kel) of Total IgG
Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Average Concentration of Total IgG Over the Dosing Interval (Cavg)
Average concentration of total IgG over the dosing interval (Cavg) was reported. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Percentage Peak Trough Fluctuation of Total IgG
The peak trough fluctuation within complete dosing interval at steady state of total IgG was reported. Both baseline corrected and un-corrected data was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Tetanus Toxoid Antibodies
Cmax was obtained directly from the concentration versus time curve.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Half-Life (t1/2) of Antigen-Specific Tetanus Toxoid Antibodies
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Tetanus Toxoid Antibodies
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. The AUC0-t of antigen-specific tetanus toxoid antibodies was measured in hour\*international units per milliliter (hr\*IU/mL).
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Tetanus Toxoid Antibodies
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Tetanus Toxoid Antibodies
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Volume of Distribution (Vd) of Antigen-Specific Tetanus Toxoid Antibodies
Vd was defined as the the theoretical volume in which the total amount of antigen-specific tetanus toxoid antibodies would need to be uniformly distributed to produce the desired blood concentration of antigen-specific tetanus toxoid antibodies. The Vd of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per international unit\*kilogram (mg\*mL/IU\*kg).
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Steady State Clearance (CLss) of Antigen-Specific Tetanus Toxoid Antibodies
Clearance of a antigen-specific tetanus toxoid antibodies was a measure of the rate at which a antigen-specific tetanus toxoid antibodies are metabolized or eliminated by normal biological processes. The CLss of antigen-specific tetanus toxoid antibodies was reported. The CLss of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg).
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Tetanus Toxoid Antibodies
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Tetanus Toxoid Antibodies
Tmax was obtained directly from the concentration versus time curve.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Rate Constant (Kel) of Antigen-Specific Tetanus Toxoid Antibodies
Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Average Concentration of Antigen-Specific Tetanus Toxoid Antibodies Over the Dosing Interval (Cavg)
Average concentration of antigen-specific tetanus toxoid antibodies over the dosing interval (Cavg) was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Percentage Peak Trough Fluctuation of Antigen-Specific Tetanus Toxoid Antibodies
The peak trough fluctuation within complete dosing interval at steady state of antigen-specific tetanus toxoid antibodies was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Cmax was obtained directly from the concentration versus time curve.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Half-Life (t1/2) of Antigen-Specific Haemophilus Influenza Type B Antibodies
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-specific haemophilus influenza Type B Antibodies was measured in hour\*microgram per milliliter (hr\*mcg/mL).
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Haemophilus Influenza Type B Antibodies
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Haemophilus Influenza Type B Antibodies
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Volume of Distribution (Vd) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Vd was defined as the the theoretical volume in which the total amount of antigen-specific haemophilus influenza type B antibodies would need to be uniformly distributed to produce the desired blood concentration of a antigen-specific haemophilus influenza type B antibodies.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Steady State Clearance (CLss) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Clearance of antigen-specific haemophilus influenza type B antibodies was a measure of the rate at which antigen-specific haemophilus influenza type B antibodies were metabolized or eliminated by normal biological processes. CLss of antigen-specific haemophilus influenza type B antibodies was measured in milliliter per hour per kilogram (mL/hr/kg).
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Tmax was obtained directly from the concentration versus time curve.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Terminal Elimination Rate Constant (Lambda z) of Antigen-Specific Haemophilus Influenza Type B Antibodies
Terminal Elimination Rate Constant (lambda z) derived if data allowed based on PK acceptance criteria
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Average Concentration of Antigen-Specific Haemophilus Influenza Type B Antibodies Over the Dosing Interval (Cavg)
Average concentration of antigen-specific haemophilus influenza type B antibodies over the dosing interval (Cavg) was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Percentage Peak Trough Fluctuation of Antigen-Specific Haemophilus Influenza Type B Antibodies
The peak trough fluctuation within complete dosing interval at steady state of antigen-specific haemophilus influenza type B antibodies was reported.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Maximum Observed Serum Concentration (Cmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
Cmax was obtained directly from the concentration versus time curve. The Cmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8, serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Half-Life (t1/2) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The t1/2 for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-pneumococcal capsular polysaccharide was measured in hour\*microgram per milliliter (hr\*mcg/mL). The AUC0-t for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The AUC0-inf for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. The AUCtau for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Volume of Distribution (Vd) of of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
Vd was defined as the the theoretical volume in which the total amount of anti-pneumococcal capsular polysaccharide would need to be uniformly distributed to produce the desired blood concentration of a anti-pneumococcal capsular polysaccharide. The Vd for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Steady State Clearance (CLss) of Anti-pneumococcal Capsular Polysaccharide Antibodies (Overall SP Serotypes)
Clearance of a anti-pneumococcal capsular polysaccharide antibodies was a measure of the rate at which a anti-pneumococcal capsular polysaccharide antibodies are metabolized or eliminated by normal biological processes. The CLss of anti-pneumococcal capsular polysaccharide antibodies was reported. The CLss of anti-pneumococcal capsular polysaccharide antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg). The CLss for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Minimum Observed Serum Concentration (Cmin) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. The Cmin for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Time to Reach the Maximum Serum Concentration (Tmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
Tmax was obtained directly from the concentration versus time curve. The Tmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Elimination Rate Constant (Kel) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The Kel for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Average Concentration of Anti-pneumococcal Capsular Polysaccharide the Dosing Interval (Cavg) (Overall SP Serotypes)
Average concentration of anti-pneumococcal capsular polysaccharide over the dosing interval (Cavg) was reported. The Cavg for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Percentage Peak Trough Fluctuation of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
The peak trough fluctuation within complete dosing interval at steady state of anti-pneumococcal capsular polysaccharide was reported. The peak trough fluctuation for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
This study was conducted at 11 sites in the United States from 30 April 2019 (first participant first visit) to 21 December 2020 (last participant last visit).
| Milestone | Kedrion IVIG 10% |
|---|---|
| Started | 47 |
| Completed | 47 |
| Not completed | 0 |
Incidence rate was defined as the mean number of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year according to pre-specified criteria.
| infections per participant-year | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 0.0 ± 0.0 |
| 28-day dosing schedule | 0.0 ± 0.0 |
The serum IgG trough levels were collected and analyzed at a central laboratory.
| grams per liter (g/L) | Kedrion IVIG 10% |
|---|---|
| Baseline | 10.317 ± 3.1342 |
| 21-day dosing schedule: Week 51 | 11.433 ± 1.7935 |
| 28-day dosing schedule: Week 52 | 10.297 ± 2.1167 |
IgG subclasses levels (IgG1, IgG2, IgG3, IgG4) were collected and analyzed at a central laboratory.
| g/L | Kedrion IVIG 10% |
|---|---|
| IgG1: Baseline | 5.798 ± 1.7504 |
| IgG1: 28-day dosing schedule: Week 16 | 5.605 ± 1.6115 |
| IgG1: 21-day dosing schedule: Week 18 | 5.968 ± 1.5094 |
| IgG1: 28-day dosing schedule: Week 32 | 5.679 ± 1.3965 |
| IgG1: 21-day dosing schedule: Week 30 | 5.979 ± 0.9430 |
| IgG1: 28-day dosing schedule: Week 48 | 5.634 ± 1.4139 |
| IgG1: 21-day dosing schedule: Week 48 | 6.210 ± 0.9430 |
| IgG2: Baseline | 3.527 ± 0.9635 |
| IgG2: 28-day dosing schedule: Week 16 | 3.419 ± 0.8803 |
| IgG2: 21-day dosing schedule: Week 18 | 4.113 ± 1.0155 |
| IgG2: 28-day dosing schedule: Week 32 | 3.458 ± 0.7705 |
| IgG2: 21-day dosing schedule: Week 30 | 4.079 ± 0.4975 |
| IgG2: 28-day dosing schedule: Week 48 | 3.475 ± 0.7848 |
| IgG2: 21-day dosing schedule: Week 48 | 4.234 ± 0.5649 |
| IgG3: Baseline | 0.405 ± 0.3109 |
| IgG3: 28-day dosing schedule: Week 16 | 0.351 ± 0.3459 |
| IgG3: 21-day dosing schedule: Week 18 | 0.271 ± 0.1239 |
| IgG3: 28-day dosing schedule: Week 32 | 0.352 ± 0.3461 |
| IgG3: 21-day dosing schedule: Week 30 | 0.249 ± 0.0885 |
| IgG3: 28-day dosing schedule: Week 48 | 0.329 ± 0.3268 |
| IgG3: 21-day dosing schedule: Week 48 | 0.253 ± 0.0658 |
| IgG4: Baseline | 0.2213 ± 0.12779 |
| IgG4: 28-day dosing schedule: Week 16 | 0.2388 ± 0.09656 |
| IgG4: 21-day dosing schedule: Week 18 | 0.2744 ± 0.06415 |
| IgG4: 28-day dosing schedule: Week 32 | 0.2425 ± 0.09290 |
| IgG4: 21-day dosing schedule: Week 30 | 0.2838 ± 0.06412 |
| IgG4: 28-day dosing schedule: Week 48 | 0.2396 ± 0.09355 |
| IgG4: 21-day dosing schedule: Week 48 | 0.2950 ± 0.05381 |
Number of participants with Total IgG trough levels \<= 6 g/L criteria were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| Number of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria | 1 |
The anti-tetanus toxoid antibody levels were collected and analyzed at a central laboratory. This antibody level was measured in international units per milliliter (IU/mL).
| IU/mL | Kedrion IVIG 10% |
|---|---|
| Baseline | 2.526 ± 1.4158 |
| 28-day dosing schedule: Week 16 | 2.589 ± 2.0770 |
| 21-day dosing schedule: Week 18 | 2.654 ± 0.9853 |
| 28-day dosing schedule: Week 32 | 2.345 ± 0.8820 |
| 21-day dosing schedule: Week 30 | 2.643 ± 0.9374 |
| 28-day dosing schedule: Week 48 | 2.207 ± 0.8565 |
| 21-day dosing schedule: Week 48 | 3.299 ± 1.3307 |
Anti-pneumococcal capsular polysaccharide antibody levels for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 were collected and analyzed at a central laboratory.
| milligrams per liter (mg/L) | Kedrion IVIG 10% |
|---|---|
| Baseline: Serotype 1 | 2.66 ± 4.820 |
| 28-day dosing schedule: Week 16: Serotype 1 | 1.55 ± 1.481 |
| 21-day dosing schedule: Week 18: Serotype 1 | 4.89 ± 5.740 |
| 28-day dosing schedule: Week 32: Serotype 1 | 1.66 ± 2.114 |
| 21-day dosing schedule: Week 30: Serotype 1 | 4.74 ± 5.692 |
| 28-day dosing schedule: Week 48: Serotype 1 | 1.49 ± 1.707 |
| 21-day dosing schedule: Week 48: Serotype 1 | 4.28 ± 4.926 |
| Baseline: Serotype 12 | 0.81 ± 1.103 |
| 28-day dosing schedule: Week 16: Serotype 12 | 0.75 ± 1.201 |
| 21-day dosing schedule: Week 18: Serotype 12 | 0.58 ± 0.175 |
| 28-day dosing schedule: Week 32: Serotype 12 | 0.86 ± 1.280 |
| 21-day dosing schedule: Week 30: Serotype 12 | 0.55 ± 0.120 |
| 28-day dosing schedule: Week 48: Serotype 12 | 0.82 ± 1.159 |
| 21-day dosing schedule: Week 48: Serotype 12 | 0.59 ± 0.090 |
| Baseline: Serotype 14 | 9.04 ± 20.383 |
| 28-day dosing schedule: Week 16: Serotype 14 | 11.88 ± 29.791 |
| 21-day dosing schedule: Week 18: Serotype 14 | 6.11 ± 3.302 |
| 28-day dosing schedule: Week 32: Serotype 14 | 11.96 ± 26.509 |
| 21-day dosing schedule: Week 30: Serotype 14 | 5.76 ± 2.752 |
| 28-day dosing schedule: Week 48: Serotype 14 | 13.02 ± 34.794 |
| 21-day dosing schedule: Week 48: Serotype 14 | 6.14 ± 3.408 |
| Baseline: Serotype 17 | 2.55 ± 4.249 |
| 28-day dosing schedule: Week 16: Serotype 17 | 2.08 ± 3.977 |
| 21-day dosing schedule: Week 18: Serotype 17 | 3.25 ± 3.146 |
| 28-day dosing schedule: Week 32: Serotype 17 | 1.89 ± 2.952 |
| 21-day dosing schedule: Week 30: Serotype 17 | 3.38 ± 4.058 |
| 28-day dosing schedule: Week 48: Serotype 17 | 1.76 ± 3.043 |
| 21-day dosing schedule: Week 48: Serotype 17 | 3.09 ± 3.111 |
| Baseline: Serotype 19 | 3.71 ± 5.275 |
| 28-day dosing schedule: Week 16: Serotype 19 | 4.95 ± 8.597 |
| 21-day dosing schedule: Week 18: Serotype 19 | 3.20 ± 1.074 |
| 28-day dosing schedule: Week 32: Serotype 19 | 3.71 ± 4.200 |
| 21-day dosing schedule: Week 30: Serotype 19 | 2.88 ± 0.686 |
| 28-day dosing schedule: Week 48: Serotype 19 | 4.25 ± 7.328 |
| 21-day dosing schedule: Week 48: Serotype 19 | 2.86 ± 0.958 |
| Baseline: Serotype 2 | 2.38 ± 2.294 |
| 28-day dosing schedule: Week 16: Serotype 2 | 2.04 ± 1.618 |
| 21-day dosing schedule: Week 18: Serotype 2 | 3.34 ± 3.701 |
| 28-day dosing schedule: Week 32: Serotype 2 | 2.11 ± 1.502 |
| 21-day dosing schedule: Week 30: Serotype 2 | 3.48 ± 4.071 |
| 28-day dosing schedule: Week 48: Serotype 2 | 2.01 ± 1.283 |
| 21-day dosing schedule: Week 48: Serotype 2 | 3.35 ± 3.342 |
| Baseline: Serotype 20 | 2.71 ± 2.296 |
| 28-day dosing schedule: Week 16: Serotype 20 | 2.63 ± 3.007 |
| 21-day dosing schedule: Week 18: Serotype 20 | 3.05 ± 1.425 |
| 28-day dosing schedule: Week 32: Serotype 20 | 2.76 ± 3.153 |
| 21-day dosing schedule: Week 30: Serotype 20 | 3.16 ± 1.614 |
| 28-day dosing schedule: Week 48: Serotype 20 | 2.51 ± 2.779 |
| 21-day dosing schedule: Week 48: Serotype 20 | 3.05 ± 1.295 |
| Baseline: Serotype 22 | 1.33 ± 1.968 |
| 28-day dosing schedule: Week 16: Serotype 22 | 0.84 ± 0.938 |
| 21-day dosing schedule: Week 18: Serotype 22 | 2.36 ± 3.554 |
| 28-day dosing schedule: Week 32: Serotype 22 | 0.83 ± 0.698 |
| 21-day dosing schedule: Week 30: Serotype 22 | 2.78 ± 4.627 |
| 28-day dosing schedule: Week 48: Serotype 22 | 0.88 ± 0.670 |
| 21-day dosing schedule: Week 48: Serotype 22 | 2.51 ± 3.652 |
| Baseline: Serotype 23 | 1.65 ± 2.336 |
| 28-day dosing schedule: Week 16: Serotype 23 | 1.42 ± 2.501 |
| 21-day dosing schedule: Week 18: Serotype 23 | 1.28 ± 0.696 |
| 28-day dosing schedule: Week 32: Serotype 23 | 1.37 ± 2.064 |
| 21-day dosing schedule: Week 30: Serotype 23 | 1.34 ± 0.607 |
| 28-day dosing schedule: Week 48: Serotype 23 | 1.47 ± 2.270 |
| 21-day dosing schedule: Week 48: Serotype 23 | 1.50 ± 0.733 |
| Baseline: Serotype 26 | 1.72 ± 1.910 |
| 28-day dosing schedule: Week 16: Serotype 26 | 1.32 ± 1.578 |
| 21-day dosing schedule: Week 18: Serotype 26 | 1.83 ± 2.050 |
| 28-day dosing schedule: Week 32: Serotype 26 | 1.36 ± 1.515 |
| 21-day dosing schedule: Week 30: Serotype 26 | 1.70 ± 1.505 |
| 28-day dosing schedule: Week 48: Serotype 26 | 1.39 ± 1.549 |
| 21-day dosing schedule: Week 48: Serotype 26 | 1.73 ± 1.482 |
| Baseline: Serotype 3 | 2.41 ± 5.964 |
| 28-day dosing schedule: Week 16: Serotype 3 | 1.41 ± 2.362 |
| 21-day dosing schedule: Week 18: Serotype 3 | 4.74 ± 7.812 |
| 28-day dosing schedule: Week 32: Serotype 3 | 1.42 ± 2.526 |
| 21-day dosing schedule: Week 30: Serotype 3 | 4.24 ± 6.480 |
| 28-day dosing schedule: Week 48: Serotype 3 | 1.12 ± 1.287 |
| 21-day dosing schedule: Week 48: Serotype 3 | 4.69 ± 7.854 |
| Baseline: Serotype 34 | 1.83 ± 2.663 |
| 28-day dosing schedule: Week 16: Serotype 34 | 1.34 ± 1.718 |
| 21-day dosing schedule: Week 18: Serotype 34 | 3.33 ± 4.843 |
| 28-day dosing schedule: Week 32: Serotype 34 | 1.30 ± 1.524 |
| 21-day dosing schedule: Week 30: Serotype 34 | 3.73 ± 6.610 |
| 28-day dosing schedule: Week 48: Serotype 34 | 1.35 ± 1.585 |
| 21-day dosing schedule: Week 48: Serotype 34 | 3.04 ± 4.276 |
| Baseline: Serotype 4 | 0.88 ± 1.366 |
| 28-day dosing schedule: Week 16: Serotype 4 | 0.54 ± 0.896 |
| 21-day dosing schedule: Week 18: Serotype 4 | 0.57 ± 0.576 |
| 28-day dosing schedule: Week 32: Serotype 4 | 1.07 ± 1.292 |
| 21-day dosing schedule: Week 30: Serotype 4 | 0.66 ± 0.434 |
| 28-day dosing schedule: Week 48: Serotype 4 | 0.89 ± 1.187 |
| 21-day dosing schedule: Week 48: Serotype 4 | 0.68 ± 0.466 |
| Baseline: Serotype 43 | 1.36 ± 0.713 |
| 28-day dosing schedule: Week 16: Serotype 43 | 1.07 ± 0.665 |
| 21-day dosing schedule: Week 18: Serotype 43 | 1.51 ± 0.645 |
| 28-day dosing schedule: Week 32: Serotype 43 | 1.08 ± 0.568 |
| 21-day dosing schedule: Week 30: Serotype 43 | 1.43 ± 0.468 |
| 28-day dosing schedule: Week 48: Serotype 43 | 1.12 ± 0.605 |
| 21-day dosing schedule: Week 48: Serotype 43 | 1.61 ± 0.482 |
| Baseline: Serotype 5 | 3.64 ± 5.551 |
| 28-day dosing schedule: Week 16: Serotype 5 | 2.68 ± 3.650 |
| 21-day dosing schedule: Week 18: Serotype 5 | 6.56 ± 9.390 |
| 28-day dosing schedule: Week 32: Serotype 5 | 2.65 ± 3.081 |
| 21-day dosing schedule: Week 30: Serotype 5 | 6.51 ± 10.172 |
| 28-day dosing schedule: Week 48: Serotype 5 | 2.44 ± 3.145 |
| 21-day dosing schedule: Week 48: Serotype 5 | 5.41 ± 7.414 |
| Baseline: Serotype 51 | 2.82 ± 5.468 |
| 28-day dosing schedule: Week 16: Serotype 51 | 1.66 ± 0.777 |
| 21-day dosing schedule: Week 18: Serotype 51 | 5.96 ± 8.691 |
| 28-day dosing schedule: Week 32: Serotype 51 | 1.65 ± 0.786 |
| 21-day dosing schedule: Week 30: Serotype 51 | 5.70 ± 7.914 |
| 28-day dosing schedule: Week 48: Serotype 51 | 1.58 ± 0.843 |
| 21-day dosing schedule: Week 48: Serotype 51 | 5.86 ± 8.456 |
| Baseline: Serotype 54 | 3.04 ± 4.819 |
| 28-day dosing schedule: Week 16: Serotype 54 | 2.33 ± 2.575 |
| 21-day dosing schedule: Week 18: Serotype 54 | 5.04 ± 6.363 |
| 28-day dosing schedule: Week 32: Serotype 54 | 2.95 ± 5.542 |
| 21-day dosing schedule: Week 30: Serotype 54 | 4.86 ± 5.637 |
| 28-day dosing schedule: Week 48: Serotype 54 | 2.53 ± 3.181 |
| 21-day dosing schedule: Week 48: Serotype 54 | 4.13 ± 3.700 |
| Baseline: Serotype 56 | 3.41 ± 8.495 |
| 28-day dosing schedule: Week 16: Serotype 56 | 2.55 ± 6.989 |
| 21-day dosing schedule: Week 18: Serotype 56 | 5.84 ± 9.970 |
| 28-day dosing schedule: Week 32: Serotype 56 | 2.17 ± 5.089 |
| 21-day dosing schedule: Week 30: Serotype 56 | 5.38 ± 8.242 |
| 28-day dosing schedule: Week 48: Serotype 56 | 2.54 ± 8.116 |
| 21-day dosing schedule: Week 48: Serotype 56 | 6.00 ± 10.338 |
| Baseline: Serotype 57 | 5.73 ± 8.398 |
| 28-day dosing schedule: Week 16: Serotype 57 | 5.11 ± 8.435 |
| 21-day dosing schedule: Week 18: Serotype 57 | 23.40 ± 48.403 |
| 28-day dosing schedule: Week 32: Serotype 57 | 5.46 ± 9.059 |
| 21-day dosing schedule: Week 30: Serotype 57 | 7.00 ± 10.268 |
| 28-day dosing schedule: Week 48: Serotype 57 | 5.31 ± 9.379 |
| 21-day dosing schedule: Week 48: Serotype 57 | 8.17 ± 12.789 |
| Baseline: Serotype 68 | 1.08 ± 1.095 |
| 28-day dosing schedule: Week 16: Serotype 68 | 0.86 ± 0.567 |
| 21-day dosing schedule: Week 18: Serotype 68 | 1.66 ± 1.555 |
| 28-day dosing schedule: Week 32: Serotype 68 | 0.93 ± 0.918 |
| 21-day dosing schedule: Week 30: Serotype 68 | 1.36 ± 1.260 |
| 28-day dosing schedule: Week 48: Serotype 68 | 0.76 ± 0.524 |
| 21-day dosing schedule: Week 48: Serotype 68 | 1.33 ± 1.233 |
| Baseline: Serotype 70 | 1.98 ± 2.911 |
| 28-day dosing schedule: Week 16: Serotype 70 | 1.43 ± 1.100 |
| 21-day dosing schedule: Week 18: Serotype 70 | 3.56 ± 5.360 |
| 28-day dosing schedule: Week 32: Serotype 70 | 1.53 ± 1.128 |
| 21-day dosing schedule: Week 30: Serotype 70 | 3.53 ± 5.776 |
| 28-day dosing schedule: Week 48: Serotype 70 | 1.48 ± 0.988 |
| 21-day dosing schedule: Week 48: Serotype 70 | 3.19 ± 3.978 |
| Baseline: Serotype 8 | 2.10 ± 2.650 |
| 28-day dosing schedule: Week 16: Serotype 8 | 1.67 ± 1.258 |
| 21-day dosing schedule: Week 18: Serotype 8 | 3.51 ± 3.440 |
| 28-day dosing schedule: Week 32: Serotype 8 | 1.86 ± 1.822 |
| 21-day dosing schedule: Week 30: Serotype 8 | 3.66 ± 4.268 |
| 28-day dosing schedule: Week 48: Serotype 8 | 1.82 ± 1.593 |
| 21-day dosing schedule: Week 48: Serotype 8 | 3.63 ± 3.479 |
| Baseline: Serotype 9 | 0.96 ± 0.694 |
| 28-day dosing schedule: Week 16: Serotype 9 | 0.77 ± 0.510 |
| 21-day dosing schedule: Week 18: Serotype 9 | 1.03 ± 0.560 |
| 28-day dosing schedule: Week 32: Serotype 9 | 0.81 ± 0.587 |
| 21-day dosing schedule: Week 30: Serotype 9 | 0.99 ± 0.503 |
| 28-day dosing schedule: Week 48: Serotype 9 | 0.75 ± 0.433 |
| 21-day dosing schedule: Week 48: Serotype 9 | 1.03 ± 0.486 |
The anti-measles antibody levels were collected and analyzed at a central laboratory.
No measurements were reported for this outcome.
The anti-haemophilus influenza type B antibody levels were collected and analyzed at central laboratory.
| micrograms per milliliter (mcg/mL) | Kedrion IVIG 10% |
|---|---|
| Baseline | 2.010 ± 1.1641 |
| 28-day dosing schedule: Week 16 | 2.547 ± 1.7879 |
| 21-day dosing schedule: Week 18 | 2.489 ± 0.9027 |
| 28-day dosing schedule: Week 32 | 2.277 ± 1.3112 |
| 21-day dosing schedule: Week 30 | 2.888 ± 0.8676 |
| 28-day dosing schedule: Week 48 | 2.183 ± 1.1944 |
| 21-day dosing schedule: Week 48 | 2.606 ± 0.8433 |
Incidence rate was defined as the mean number of any infection other than acute serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year. Incidence rate of any infection other than acute bacterial serious infections collected by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.
| infections per participant year | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 4.4 ± 2.11 |
| 28-day dosing schedule | 1.6 ± 1.27 |
Duration of any infection other than serious acute bacterial infections (in days) was calculated as date of stop of infection - date of start of infection + 1. Duration of any infection other than serious acute bacterial infections collected by the by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.
| days | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 41.0 ± 65.14 |
| 28-day dosing schedule | 24.9 ± 51.36 |
Incidence rate was defined as the mean number of fever episodes per participant-year. Incidence rate of fever episodes collected by the participant/participant's parent(s)/legal guardian(s) in the participant diary or during clinic visit were reported.
| fever episodes per participant year | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 0.0 ± 0.0 |
| 28-day dosing schedule | 0.2 ± 0.42 |
Duration of fever episodes in participants was reported.
| days | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule | 3.0 ± 2.24 |
Duration of overall participants hospitalization was reported.
| days | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 6.0 |
| 28-day dosing schedule | 3.3 ± 1.53 |
Duration of participants hospitalization due to infection was reported.
No measurements were reported for this outcome.
Incidence rate was defined as the mean number of antibiotics episodes per participant year. Incidence rate of participants on antibiotics for treatment of any kind of infections was reported.
| antibiotics episodes/participant year | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 3.8 ± 1.95 |
| 28-day dosing schedule | 2.1 ± 1.46 |
Duration of participants on antibiotics for treatment of any kind of infection was reported.
| days | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 13.1 ± 5.72 |
| 28-day dosing schedule | 13.3 ± 35.86 |
Duration of missed school/work/other major activities due to infections was reported.
| days | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 25.3 ± 25.11 |
| 28-day dosing schedule | 4.7 ± 2.73 |
23-item PedsQL generic core scales was a modular approach to measure health-related Quality of Life (QoL) in healthy children, adolescents and those with acute and chronic health conditions. The total scale score (23 items) consisted of Physical Health Summary Score (8 items) and Psychosocial Health SummaryScore (15 items). Physical health summary included Physical Functioning (8 items) and Psychosocial health summary score included Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale, where higher scores indicated better QoL. The overall range for total PedsQL score (23 items) was 0 to 100, with higher score indicated better QoL. Data for 18-25 years and \>25 years age group was reported.
| score on a scale | Kedrion IVIG 10% |
|---|---|
| Baseline (18 to 25 years) | 87.5 ± 16.14 |
| 21-day dosing schedule: Week 24 (18 to 25 years) | 68.5 |
| 21-day dosing schedule: Week 51 (18 to 25 years) | 58.7 |
| 28-day dosing schedule: Week 24 (18 to 25 years) | 100.0 |
| 28-day dosing schedule: Week 52 (18 to 25 years) | 100.0 |
| Baseline (> 25 years) | 76.2 ± 16.53 |
| 21-day dosing schedule: Week 24 (> 25 years) | 65.1 ± 15.92 |
| 21-day dosing schedule: Week 51 (> 25 years) | 70.3 ± 18.93 |
| 28-day dosing schedule: Week 24 (> 25 years) | 78.3 ± 17.02 |
| 28-day dosing schedule: Week 52 (> 25 years) | 77.8 ± 18.42 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAE was defined as an AE with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious TEAEs.
| Participants | Kedrion IVIG 10% |
|---|---|
| Participants with TEAEs: 21-day dosing schedule: | 8 |
| Participants with TEAEs: 28-day dosing schedule | 38 |
| Participants with Serious TEAEs: 21-day dosing schedule | 1 |
| Participants with Serious TEAEs: 28-day dosing schedule | 3 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A SAE was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. A TEAE was defined as an AE with an onset that occurs after receiving study drug. Number of TEAEs and Serious TEAEs were reported.
| adverse events | Kedrion IVIG 10% |
|---|---|
| TEAEs: 21-day dosing schedule | 81 |
| TEAEs: 28-day dosing schedule | 324 |
| Serious TEAEs: 21-day dosing schedule | 1 |
| Serious TEAEs: 28-day dosing schedule | 4 |
An AE was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. Number of drug related infusion AEs were reported.
| adverse events | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 3 |
| 28-day dosing schedule | 60 |
Percentage of participants who experienced at least one drug related infusion AEs were reported.
| percentage of participants | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 25.0 |
| 28-day dosing schedule | 43.6 |
Number of infusions with decreased infusion rate due to AEs were reported.
| Infusions | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 0 |
| 28-day dosing schedule | 9 |
The number of infusions with one or more infusion associated AEs were reported collectively for 21 and 28-day dosing schedule up to Week 52.
| Infusions | Kedrion IVIG 10% |
|---|---|
| Number of Infusions With One or More Infusion Associated Adverse Events (AEs) | 80 |
Vital signs included body temperature, systolic and diastolic blood pressure, heart rate and weight. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 0 |
| 28-day dosing schedule | 0 |
Physical examination included the examination of general appearance, skin, neck, eyes, ears, nose, throat, cardiovascular assessment including rhythm, and presence of other cardiac abnormalities (for example gallops, murmurs, cardiomegaly), respiratory system, gastrointestinal system, genitourinary system and musculoskeletal system. Clinical significance was decided by the investigator. The number of participants with clinically significant changes from baseline in physical examination were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| 21-day dosing schedule | 0 |
| 28-day dosing schedule | 0 |
Laboratory parameters included chemistry, hematology and urinalysis. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| Hematology: 21-day dosing schedule | 3 |
| Hematology: 28-day dosing schedule | 7 |
| Chemistry: 21-day dosing schedule | 1 |
| Chemistry: 28-day dosing schedule | 5 |
| Urinalysis: 21-day dosing schedule | 2 |
| Urinalysis: 28-day dosing schedule | 4 |
Intravascular hemolysis testing was performed by using coomb's test. The coomb's assessment was performed at a central laboratory.
| Participants | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 14 |
| 21-day dosing schedule: Week 18 | 4 |
Number of participants with positive urine hemosiderin test were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0 |
| 21-day dosing schedule: Week 18 | 0 |
Number of participants with plasma-free haemoglobin level more than or equal to (\>=) 69 milligrams per deciliter (mg/dL) were consisdered as abormal and were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 10 |
| 21-day dosing schedule : Week 18 | 2 |
Number of participants with abnormal serum haptoglobin level were reported.
| Participants | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 10 |
| 21-day dosing schedule: Week 18 | 0 |
Cmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.
| milligrams per deciliter (mg/dL) | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 1280 ± 433 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 1520 ± 185 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 2300 ± 466 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 2680 ± 282 |
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.
| hours | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 158 ± 48.4 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 107 ± 45.4 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 896 ± 269 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 587 ± 58.2 |
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.
| day*milligram per deciliter (day*mg/dL) | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 9520 ± 3310 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 8380 ± 1670 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 37300 ± 7720 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 31700 ± 6030 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.
| hr*g/L | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 2710.991 ± 733.1555 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 2435.562 ± 471.842 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 22065.3148 ± 5061.15798 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 18292.68 ± 2869.244 |
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.
| day*mg/dL | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 9840 ± 3330 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 8860 ± 1630 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 38000 ± 6500 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 34000 ± 3630 |
Vd was defined as the the theoretical volume in which the total amount of total IgG would need to be uniformly distributed to produce the desired blood concentration of a total IgG. Both baseline corrected and un-corrected data was reported.
| deciliters per kilogram (dL/kg) | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 0.532 ± 0.108 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 0.563 ± 0.161 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 0.697 ± 0.118 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 0.667 ± 0.0398 |
Clearance of a total IgG was a measure of the rate at which a total IgG is metabolized or eliminated by normal biological processes. CLss of total IgG was measured in milliliters per hour per kilogram (mL/hr/kg). Both baseline corrected and un-corrected data was reported.
| dL/day/kg | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 0.0559 ± 0.0102 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 0.0763 ± 0.00342 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 0.0140 ± 0.00355 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 0.0193 ± 0.00305 |
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.
| mg/dL | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 0.00 ± 0.00 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 0.00 ± 0.00 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 994 ± 200 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 1140 ± 150 |
Tmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.
| hours | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 0.515 (0.500 to 23.8) |
| Baseline corrected: 21-day dosing schedule: Week 18 | 0.530 (0.500 to 2.02) |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 0.515 (0.500 to 23.8) |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 0.530 (0.500 to 2.02) |
Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.
| 1/hour | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 0.0048 ± 0.00156 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 0.00743 ± 0.00300 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 0.000845 ± 0.000270 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 0.00119 ± 0.000117 |
Average concentration of total IgG over the dosing interval (Cavg) was reported. Both baseline corrected and un-corrected data was reported.
| mg/dL | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 354 ± 117 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 424 ± 78.6 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 1370 ± 239 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 1630 ± 175 |
The peak trough fluctuation within complete dosing interval at steady state of total IgG was reported. Both baseline corrected and un-corrected data was reported.
| percent fluctuation | Kedrion IVIG 10% |
|---|---|
| Baseline corrected: 28-day dosing schedule: Week 16 | 364 ± 70.7 |
| Baseline corrected: 21-day dosing schedule: Week 18 | 360 ± 56.3 |
| Baseline uncorrected: 28-day dosing schedule: Week 16 | 94.3 ± 30.6 |
| Baseline uncorrected: 21-day dosing schedule: Week 18 | 95.0 ± 7.92 |
Cmax was obtained directly from the concentration versus time curve.
| IU/mL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 6.533 ± 2.9955 |
| 21-day dosing schedule: Week 18 | 7.400 ± 2.0988 |
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
| hours | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 618.97 ± 320.008 |
| 21-day dosing schedule: Week 18 | 1097.75 ± 1061.343 |
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. The AUC0-t of antigen-specific tetanus toxoid antibodies was measured in hour\*international units per milliliter (hr\*IU/mL).
| hr*IU/mL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 2037.7497 ± 568.85079 |
| 21-day dosing schedule: Week 18 | 1805.9758 ± 210.37005 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
| hour*microgram per milliliter(hr*mcg/mL) | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 4171.4977 ± 2513.60199 |
| 21-day dosing schedule: Week 18 | 10142.0162 ± 12855.54687 |
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.
| hr*IU/mL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 1997.8829 ± 526.07254 |
| 21-day dosing schedule: Week 18 | 1934.6533 ± 317.07241 |
Vd was defined as the the theoretical volume in which the total amount of antigen-specific tetanus toxoid antibodies would need to be uniformly distributed to produce the desired blood concentration of antigen-specific tetanus toxoid antibodies. The Vd of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per international unit\*kilogram (mg\*mL/IU\*kg).
| mg*mL/IU*kg | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 263.3132 ± 157.80776 |
| 21-day dosing schedule: Week 18 | 688.4792 ± 792.01235 |
Clearance of a antigen-specific tetanus toxoid antibodies was a measure of the rate at which a antigen-specific tetanus toxoid antibodies are metabolized or eliminated by normal biological processes. The CLss of antigen-specific tetanus toxoid antibodies was reported. The CLss of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg).
| mg*mL/hr*IU*kg | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.2741 ± 0.06916 |
| 21-day dosing schedule: Week 18 | 0.3724 ± 0.05201 |
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.
| IU/mL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 1.833 ± 0.5531 |
| 21-day dosing schedule: Week 18 | 2.240 ± 0.4827 |
Tmax was obtained directly from the concentration versus time curve.
| hours | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 2.000 (0.48 to 168.00) |
| 21-day dosing schedule: Week 18 | 70.450 (1.97 to 71.25) |
Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
| 1/hour | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.0014 ± 0.00062 |
| 21-day dosing schedule: Week 18 | 0.0011 ± 0.00065 |
Average concentration of antigen-specific tetanus toxoid antibodies over the dosing interval (Cavg) was reported.
| IU/mL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 2.9730 ± 0.78285 |
| 21-day dosing schedule: Week 18 | 3.8386 ± 0.62911 |
The peak trough fluctuation within complete dosing interval at steady state of antigen-specific tetanus toxoid antibodies was reported.
| percent fluctuation | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 154.7237 ± 63.56527 |
| 21-day dosing schedule: Week 18 | 145.9127 ± 55.92179 |
Cmax was obtained directly from the concentration versus time curve.
| milligram per deciliter (mg/dL) | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.682 ± 0.204 |
| 21-day dosing schedule: Week 18 | 0.787 ± 0.141 |
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
| hours | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 682 ± 488 |
| 21-day dosing schedule: Week 18 | 364 ± 52.2 |
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-specific haemophilus influenza Type B Antibodies was measured in hour\*microgram per milliliter (hr\*mcg/mL).
| day*mg/dL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 9.80 ± 4.35 |
| 21-day dosing schedule: Week 18 | 8.80 ± 3.02 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
| hr*mcg/mL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 5087.4141 ± 3563.09258 |
| 21-day dosing schedule: Week 18 | 4223.1698 ± 493.35835 |
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.
| day*mg/dL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 9.80 ± 4.35 |
| 21-day dosing schedule: Week 18 | 9.90 ± 2.03 |
Vd was defined as the the theoretical volume in which the total amount of antigen-specific haemophilus influenza type B antibodies would need to be uniformly distributed to produce the desired blood concentration of a antigen-specific haemophilus influenza type B antibodies.
| milligrams per kilogram (mL/kg) | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 245966.4231 ± 160457.69395 |
| 21-day dosing schedule: Week 18 | 182273.0408 ± 88143.84190 |
Clearance of antigen-specific haemophilus influenza type B antibodies was a measure of the rate at which antigen-specific haemophilus influenza type B antibodies were metabolized or eliminated by normal biological processes. CLss of antigen-specific haemophilus influenza type B antibodies was measured in milliliter per hour per kilogram (mL/hr/kg).
| mL/hr/kg | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 253.5539 ± 75.88763 |
| 21-day dosing schedule: Week 18 | 299.5030 ± 100.44087 |
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.
| mg/dL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.215 ± 0.134 |
| 21-day dosing schedule: Week 18 | 0.225 ± 0.0623 |
Tmax was obtained directly from the concentration versus time curve.
| hours | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.500 (0.480 to 24.3) |
| 21-day dosing schedule: Week 18 | 2.02 (0.500 to 502) |
Terminal Elimination Rate Constant (lambda z) derived if data allowed based on PK acceptance criteria
| 1/hour | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.00148 ± 0.000815 |
| 21-day dosing schedule: Week 18 | 0.00192 ± 0.000276 |
Average concentration of antigen-specific haemophilus influenza type B antibodies over the dosing interval (Cavg) was reported.
| mg/dL | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 0.352 ± 0.155 |
| 21-day dosing schedule: Week 18 | 0.474 ± 0.0971 |
The peak trough fluctuation within complete dosing interval at steady state of antigen-specific haemophilus influenza type B antibodies was reported.
| percent fluctuation | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16 | 141 ± 72.8 |
| 21-day dosing schedule: Week 18 | 88.1 ± 66.9 |
Cmax was obtained directly from the concentration versus time curve. The Cmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8, serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| mg/L | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 3.478 ± 2.7623 |
| 28-day dosing schedule: Week 16: Serotype 12 | 1.256 ± 1.2458 |
| 28-day dosing schedule: Week 16: Serotype 14 | 20.378 ± 46.3772 |
| 28-day dosing schedule: Week 16: Serotype 17 | 4.350 ± 5.6783 |
| 28-day dosing schedule: Week 16: Serotype 19 | 7.767 ± 8.5255 |
| 28-day dosing schedule: Week 16: Serotype 2 | 3.822 ± 1.2758 |
| 28-day dosing schedule: Week 16: Serotype 20 | 4.728 ± 3.0665 |
| 28-day dosing schedule: Week 16: Serotype 22 | 2.050 ± 1.3382 |
| 28-day dosing schedule: Week 16: Serotype 23 | 3.039 ± 3.3482 |
| 28-day dosing schedule: Week 16: Serotype 26 | 2.433 ± 1.3569 |
| 28-day dosing schedule: Week 16: Serotype 3 | 2.933 ± 1.6150 |
| 28-day dosing schedule: Week 16: Serotype 4 | 0.685 ± 0.2410 |
| 28-day dosing schedule: Week 16: Serotype 34 | 2.472 ± 0.9940 |
| 28-day dosing schedule: Week 16: Serotype 43 | 2.572 ± 1.1108 |
| 28-day dosing schedule: Week 16: Serotype 5 | 5.217 ± 4.0965 |
| 28-day dosing schedule: Week 16: Serotype 51 | 3.611 ± 1.3788 |
| 28-day dosing schedule: Week 16: Serotype 54 | 4.806 ± 2.0783 |
| 28-day dosing schedule: Week 16: Serotype 56 | 5.778 ± 11.7004 |
| 28-day dosing schedule: Week 16: Serotype 57 | 12.511 ± 21.4792 |
| 28-day dosing schedule: Week 16: Serotype 68 | 1.806 ± 0.8033 |
| 28-day dosing schedule: Week 16: Serotype 70 | 3.228 ± 1.6080 |
| 28-day dosing schedule: Week 16: Serotype 8 | 3.683 ± 2.6600 |
| 28-day dosing schedule: Week 16: Serotype 9 | 1.583 ± 0.7148 |
| 21-day dosing schedule: Week 18: Serotype 1 | 8.440 ± 8.3182 |
| 21-day dosing schedule: Week 18: Serotype 12 | 1.140 ± 0.1673 |
| 21-day dosing schedule: Week 18: Serotype 14 | 11.280 ± 3.5053 |
| 21-day dosing schedule: Week 18: Serotype 17 | 5.860 ± 4.0930 |
| 21-day dosing schedule: Week 18: Serotype 19 | 6.440 ± 1.0691 |
| 21-day dosing schedule: Week 18: Serotype 2 | 6.180 ± 4.6370 |
| 21-day dosing schedule: Week 18: Serotype 20 | 5.580 ± 1.8754 |
| 21-day dosing schedule: Week 18: Serotype 22 | 4.420 ± 5.4422 |
| 21-day dosing schedule: Week 18: Serotype 23 | 2.360 ± 0.8620 |
| 21-day dosing schedule: Week 18: Serotype 26 | 3.340 ± 2.5373 |
| 21-day dosing schedule: Week 18: Serotype 3 | 9.720 ± 12.7874 |
| 21-day dosing schedule: Week 18: Serotype 34 | 5.060 ± 6.2843 |
| 21-day dosing schedule: Week 18: Serotype 4 | 0.980 ± 0.6301 |
| 21-day dosing schedule: Week 18: Serotype 43 | 2.660 ± 0.7403 |
| 21-day dosing schedule: Week 18: Serotype 5 | 10.160 ± 12.4969 |
| 21-day dosing schedule: Week 18: Serotype 51 | 11.700 ± 14.2886 |
| 21-day dosing schedule: Week 18: Serotype 54 | 9.820 ± 10.6338 |
| 21-day dosing schedule: Week 18: Serotype 56 | 13.300 ± 19.3380 |
| 21-day dosing schedule: Week 18: Serotype 57 | 5.825 ± 0.9878 |
| 21-day dosing schedule: Week 18: Serotype 68 | 2.460 ± 1.7009 |
| 21-day dosing schedule: Week 18: Serotype 70 | 6.260 ± 7.0741 |
| 21-day dosing schedule: Week 18: Serotype 8 | 6.120 ± 4.5510 |
| 21-day dosing schedule: Week 18: Serotype 9 | 1.980 ± 0.7294 |
t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The t1/2 for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| hours | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 533.06 ± 279.860 |
| 28-day dosing schedule: Week 16: Serotype 12 | 415.27 ± 104.179 |
| 28-day dosing schedule: Week 16: Serotype 14 | 737.33 ± 293.005 |
| 28-day dosing schedule: Week 16: Serotype 17 | 568.11 ± 184.079 |
| 28-day dosing schedule: Week 16: Serotype 19 | 794.76 ± 365.625 |
| 28-day dosing schedule: Week 16: Serotype 2 | 943.63 ± 597.812 |
| 28-day dosing schedule: Week 16: Serotype 20 | 977.87 ± 511.568 |
| 28-day dosing schedule: Week 16: Serotype 22 | 574.22 ± 258.366 |
| 28-day dosing schedule: Week 16: Serotype 23 | 837.29 ± 476.321 |
| 28-day dosing schedule: Week 16: Serotype 26 | 638.60 ± 285.966 |
| 28-day dosing schedule: Week 16: Serotype 3 | 626.69 ± 275.200 |
| 28-day dosing schedule: Week 16: Serotype 34 | 680.14 ± 400.291 |
| 28-day dosing schedule: Week 16: Serotype 4 | 522.15 ± 39.466 |
| 28-day dosing schedule: Week 16: Serotype 43 | 573.32 ± 191.776 |
| 28-day dosing schedule: Week 16: Serotype 5 | 632.03 ± 220.955 |
| 28-day dosing schedule: Week 16: Serotype 51 | 794.63 ± 474.015 |
| 28-day dosing schedule: Week 16: Serotype 54 | 1184.97 ± 1088.054 |
| 28-day dosing schedule: Week 16: Serotype 56 | 527.75 ± 144.729 |
| 28-day dosing schedule: Week 16: Serotype 57 | 1346.21 ± 1574.359 |
| 28-day dosing schedule: Week 16: Serotype 68 | 688.31 ± 354.982 |
| 28-day dosing schedule: Week 16: Serotype 70 | 709.41 ± 282.061 |
| 28-day dosing schedule: Week 16: Serotype 8 | 562.30 ± 138.178 |
| 28-day dosing schedule: Week 16: Serotype 9 | 555.66 ± 274.555 |
| 21-day dosing schedule: Week 18: Serotype 1 | 813.74 |
| 21-day dosing schedule: Week 18: Serotype 12 | 498.21 ± 105.271 |
| 21-day dosing schedule: Week 18: Serotype 14 | 1467.24 |
| 21-day dosing schedule: Week 18: Serotype 17 | 1161.62 ± 409.606 |
| 21-day dosing schedule: Week 18: Serotype 19 | 839.73 ± 867.812 |
| 21-day dosing schedule: Week 18: Serotype 2 | 860.60 |
| 21-day dosing schedule: Week 18: Serotype 20 | 779.88 |
| 21-day dosing schedule: Week 18: Serotype 22 | 966.61 ± 104.462 |
| 21-day dosing schedule: Week 18: Serotype 23 | 805.76 ± 155.609 |
| 21-day dosing schedule: Week 18: Serotype 26 | 900.44 |
| 21-day dosing schedule: Week 18: Serotype 3 | 292.95 |
| 21-day dosing schedule: Week 18: Serotype 34 | 820.04 ± 92.314 |
| 21-day dosing schedule: Week 18: Serotype 4 | 638.35 ± 549.756 |
| 21-day dosing schedule: Week 18: Serotype 43 | 295.34 ± 120.334 |
| 21-day dosing schedule: Week 18: Serotype 5 | 825.99 |
| 21-day dosing schedule: Week 18: Serotype 51 | 813.32 |
| 21-day dosing schedule: Week 18: Serotype 54 | 754.20 |
| 21-day dosing schedule: Week 18: Serotype 56 | 931.50 |
| 21-day dosing schedule: Week 18: Serotype 68 | 259.63 |
| 21-day dosing schedule: Week 18: Serotype 70 | 1437.71 ± 1083.055 |
| 21-day dosing schedule: Week 18: Serotype 8 | 616.54 |
| 21-day dosing schedule: Week 18: Serotype 9 | 890.30 |
Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-pneumococcal capsular polysaccharide was measured in hour\*microgram per milliliter (hr\*mcg/mL). The AUC0-t for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| hr*mg/L | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 1267.2703 ± 1231.86109 |
| 28-day dosing schedule: Week 16: Serotype 12 | 481.8080 ± 615.13837 |
| 28-day dosing schedule: Week 16: Serotype 14 | 7680.6757 ± 17443.37339 |
| 28-day dosing schedule: Week 16: Serotype 17 | 1707.2987 ± 2326.27590 |
| 28-day dosing schedule: Week 16: Serotype 19 | 3264.5178 ± 4922.67289 |
| 28-day dosing schedule: Week 16: Serotype 2 | 1462.1037 ± 491.94211 |
| 28-day dosing schedule: Week 16: Serotype 20 | 1776.5915 ± 1472.71297 |
| 28-day dosing schedule: Week 16: Serotype 22 | 767.3831 ± 752.08067 |
| 28-day dosing schedule: Week 16: Serotype 23 | 1206.7604 ± 1547.47617 |
| 28-day dosing schedule: Week 16: Serotype 26 | 929.6216 ± 696.05624 |
| 28-day dosing schedule: Week 16: Serotype 3 | 940.1352 ± 397.58653 |
| 28-day dosing schedule: Week 16: Serotype 34 | 916.8877 ± 339.74807 |
| 28-day dosing schedule: Week 16: Serotype 4 | 245.8296 ± 89.81281 |
| 28-day dosing schedule: Week 16: Serotype 43 | 901.9934 ± 415.28147 |
| 28-day dosing schedule: Week 16: Serotype 5 | 1882.0174 ± 1606.54653 |
| 28-day dosing schedule: Week 16: Serotype 51 | 1313.1756 ± 285.57756 |
| 28-day dosing schedule: Week 16: Serotype 54 | 1659.0010 ± 487.17054 |
| 28-day dosing schedule: Week 16: Serotype 56 | 2361.1009 ± 5435.67901 |
| 28-day dosing schedule: Week 16: Serotype 57 | 5140.5242 ± 10426.05050 |
| 28-day dosing schedule: Week 16: Serotype 68 | 637.6826 ± 180.23219 |
| 28-day dosing schedule: Week 16: Serotype 70 | 1239.3842 ± 746.05163 |
| 28-day dosing schedule: Week 16: Serotype 8 | 1396.1732 ± 1343.80361 |
| 28-day dosing schedule: Week 16: Serotype 9 | 545.3315 ± 201.37388 |
| 21-day dosing schedule: Week 18: Serotype 1 | 3361.3444 ± 3529.24121 |
| 21-day dosing schedule: Week 18: Serotype 12 | 364.7574 ± 66.07380 |
| 21-day dosing schedule: Week 18: Serotype 14 | 4026.2582 ± 1827.76472 |
| 21-day dosing schedule: Week 18: Serotype 17 | 2327.4433 ± 1869.77732 |
| 21-day dosing schedule: Week 18: Serotype 19 | 2139.8818 ± 546.99394 |
| 21-day dosing schedule: Week 18: Serotype 2 | 2388.1819 ± 2054.90148 |
| 21-day dosing schedule: Week 18: Serotype 20 | 2088.0431 ± 956.15600 |
| 21-day dosing schedule: Week 18: Serotype 22 | 1728.1721 ± 2363.07921 |
| 21-day dosing schedule: Week 18: Serotype 23 | 826.4154 ± 390.75602 |
| 21-day dosing schedule: Week 18: Serotype 26 | 1199.7678 ± 1115.65007 |
| 21-day dosing schedule: Week 18: Serotype 3 | 3834.6179 ± 5425.47048 |
| 21-day dosing schedule: Week 18: Serotype 34 | 2095.6088 ± 2982.98719 |
| 21-day dosing schedule: Week 18: Serotype 4 | 363.5605 ± 289.99268 |
| 21-day dosing schedule: Week 18: Serotype 43 | 919.1971 ± 290.08829 |
| 21-day dosing schedule: Week 18: Serotype 5 | 4050.8597 ± 5582.10279 |
| 21-day dosing schedule: Week 18: Serotype 51 | 4775.1477 ± 6034.17097 |
| 21-day dosing schedule: Week 18: Serotype 54 | 3849.0042 ± 4696.54103 |
| 21-day dosing schedule: Week 18: Serotype 56 | 5069.9328 ± 7483.01937 |
| 21-day dosing schedule: Week 18: Serotype 57 | 1946.7526 ± 134.44174 |
| 21-day dosing schedule: Week 18: Serotype 68 | 900.2735 ± 757.57732 |
| 21-day dosing schedule: Week 18: Serotype 70 | 2385.0419 ± 3013.20369 |
| 21-day dosing schedule: Week 18: Serotype 8 | 2555.3317 ± 2162.87976 |
| 21-day dosing schedule: Week 18: Serotype 9 | 707.9849 ± 310.25117 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The AUC0-inf for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| hr*mg/L | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 835.7493 |
| 28-day dosing schedule: Week 16: Serotype 17 | 815.5984 |
| 28-day dosing schedule: Week 16: Serotype 22 | 706.0824 ± 101.30543 |
| 28-day dosing schedule: Week 16: Serotype 3 | 753.3039 |
| 28-day dosing schedule: Week 16: Serotype 56 | 871.0663 |
| 28-day dosing schedule: Week 16: Serotype 9 | 494.5129 |
| 21-day dosing schedule: Week 18: Serotype 43 | 1072.8342 |
AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. The AUCtau for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| hr*mg/L | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 1295.2208 ± 1284.98717 |
| 28-day dosing schedule: Week 16: Serotype 12 | 496.5246 ± 652.01919 |
| 28-day dosing schedule: Week 16: Serotype 14 | 7938.1617 ± 18005.53693 |
| 28-day dosing schedule: Week 16: Serotype 17 | 1128.6509 ± 606.69308 |
| 28-day dosing schedule: Week 16: Serotype 19 | 2051.7286 ± 805.43957 |
| 28-day dosing schedule: Week 16: Serotype 2 | 1437.7169 ± 551.52102 |
| 28-day dosing schedule: Week 16: Serotype 20 | 1738.1297 ± 1558.89268 |
| 28-day dosing schedule: Week 16: Serotype 22 | 759.1847 ± 785.00558 |
| 28-day dosing schedule: Week 16: Serotype 23 | 1221.7947 ± 1608.36169 |
| 28-day dosing schedule: Week 16: Serotype 26 | 929.6706 ± 739.10055 |
| 28-day dosing schedule: Week 16: Serotype 3 | 902.9745 ± 415.50944 |
| 28-day dosing schedule: Week 16: Serotype 34 | 879.5261 ± 347.31703 |
| 28-day dosing schedule: Week 16: Serotype 4 | 241.3102 ± 93.08585 |
| 28-day dosing schedule: Week 16: Serotype 43 | 934.7032 ± 507.01946 |
| 28-day dosing schedule: Week 16: Serotype 5 | 1525.6893 ± 617.53144 |
| 28-day dosing schedule: Week 16: Serotype 51 | 1327.8807 ± 304.68999 |
| 28-day dosing schedule: Week 16: Serotype 54 | 1665.6043 ± 473.20463 |
| 28-day dosing schedule: Week 16: Serotype 56 | 2456.3187 ± 5608.60157 |
| 28-day dosing schedule: Week 16: Serotype 57 | 5157.6297 ± 10068.88936 |
| 28-day dosing schedule: Week 16: Serotype 68 | 646.0577 ± 303.83828 |
| 28-day dosing schedule: Week 16: Serotype 70 | 1242.0569 ± 791.72945 |
| 28-day dosing schedule: Week 16: Serotype 8 | 1112.3875 ± 364.77366 |
| 28-day dosing schedule: Week 16: Serotype 9 | 549.2854 ± 205.21945 |
| 21-day dosing schedule: Week 18: Serotype 1 | 3427.1894 ± 4395.22135 |
| 21-day dosing schedule: Week 18: Serotype 12 | 340.6625 ± 40.16239 |
| 21-day dosing schedule: Week 18: Serotype 14 | 4203.7328 ± 2074.59529 |
| 21-day dosing schedule: Week 18: Serotype 17 | 2120.4069 ± 1774.61729 |
| 21-day dosing schedule: Week 18: Serotype 19 | 2588.0431 ± 884.21458 |
| 21-day dosing schedule: Week 18: Serotype 2 | 1995.4796 ± 1312.64625 |
| 21-day dosing schedule: Week 18: Serotype 20 | 2571.9984 ± 1782.65587 |
| 21-day dosing schedule: Week 18: Serotype 22 | 860.7046 ± 377.70459 |
| 21-day dosing schedule: Week 18: Serotype 23 | 1074.8702 ± 591.84867 |
| 21-day dosing schedule: Week 18: Serotype 26 | 1640.1471 ± 1585.98684 |
| 21-day dosing schedule: Week 18: Serotype 3 | 6340.4080 ± 9208.98601 |
| 21-day dosing schedule: Week 18: Serotype 34 | 871.0315 ± 46.94825 |
| 21-day dosing schedule: Week 18: Serotype 4 | 464.1417 ± 438.74819 |
| 21-day dosing schedule: Week 18: Serotype 43 | 971.2482 ± 311.33350 |
| 21-day dosing schedule: Week 18: Serotype 5 | 1536.7299 ± 239.98044 |
| 21-day dosing schedule: Week 18: Serotype 51 | 5984.7197 ± 8063.82766 |
| 21-day dosing schedule: Week 18: Serotype 54 | 4422.4410 ± 5245.59189 |
| 21-day dosing schedule: Week 18: Serotype 56 | 6780.9969 ± 9967.85603 |
| 21-day dosing schedule: Week 18: Serotype 57 | 2280.6541 ± 245.58661 |
| 21-day dosing schedule: Week 18: Serotype 68 | 1209.1992 ± 1169.34365 |
| 21-day dosing schedule: Week 18: Serotype 70 | 1136.7545 ± 243.27839 |
| 21-day dosing schedule: Week 18: Serotype 8 | 2145.6232 ± 1950.12455 |
| 21-day dosing schedule: Week 18: Serotype 9 | 764.0375 ± 331.36438 |
Vd was defined as the the theoretical volume in which the total amount of anti-pneumococcal capsular polysaccharide would need to be uniformly distributed to produce the desired blood concentration of a anti-pneumococcal capsular polysaccharide. The Vd for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| mL/kg | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 329057.3200 |
| 28-day dosing schedule: Week 16: Serotype 17 | 341197.1700 |
| 28-day dosing schedule: Week 16: Serotype 22 | 231539.8050 ± 104298.38458 |
| 28-day dosing schedule: Week 16: Serotype 3 | 226738.9500 |
| 28-day dosing schedule: Week 16: Serotype 56 | 342896.0600 |
| 28-day dosing schedule: Week 16: Serotype 9 | 526016.9000 |
| 21-day dosing schedule: Week 18: Serotype 43 | 283171.4700 |
Clearance of a anti-pneumococcal capsular polysaccharide antibodies was a measure of the rate at which a anti-pneumococcal capsular polysaccharide antibodies are metabolized or eliminated by normal biological processes. The CLss of anti-pneumococcal capsular polysaccharide antibodies was reported. The CLss of anti-pneumococcal capsular polysaccharide antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg). The CLss for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| mg*mL/hr*IU*kg | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 860.4600 |
| 28-day dosing schedule: Week 16: Serotype 17 | 862.3000 |
| 28-day dosing schedule: Week 16: Serotype 22 | 604.0850 ± 190.31779 |
| 28-day dosing schedule: Week 16: Serotype 3 | 705.5700 |
| 28-day dosing schedule: Week 16: Serotype 56 | 854.8300 |
| 28-day dosing schedule: Week 16: Serotype 9 | 1441.7300 |
| 21-day dosing schedule: Week 18: Serotype 43 | 849.0400 |
Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. The Cmin for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| mg/L | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 1.167 ± 0.7577 |
| 28-day dosing schedule: Week 16: Serotype 12 | 0.528 ± 0.8259 |
| 28-day dosing schedule: Week 16: Serotype 14 | 8.361 ± 19.9012 |
| 28-day dosing schedule: Week 16: Serotype 17 | 2.328 ± 4.4311 |
| 28-day dosing schedule: Week 16: Serotype 19 | 3.783 ± 6.2568 |
| 28-day dosing schedule: Week 16: Serotype 2 | 1.656 ± 0.8487 |
| 28-day dosing schedule: Week 16: Serotype 20 | 1.689 ± 0.7522 |
| 28-day dosing schedule: Week 16: Serotype 22 | 0.817 ± 1.0257 |
| 28-day dosing schedule: Week 16: Serotype 23 | 1.228 ± 1.8588 |
| 28-day dosing schedule: Week 16: Serotype 26 | 0.978 ± 0.6804 |
| 28-day dosing schedule: Week 16: Serotype 3 | 0.950 ± 0.5924 |
| 28-day dosing schedule: Week 16: Serotype 34 | 1.033 ± 0.6903 |
| 28-day dosing schedule: Week 16: Serotype 4 | 0.277 ± 0.1235 |
| 28-day dosing schedule: Week 16: Serotype 43 | 0.983 ± 0.6600 |
| 28-day dosing schedule: Week 16: Serotype 5 | 2.306 ± 3.2598 |
| 28-day dosing schedule: Week 16: Serotype 51 | 1.406 ± 0.4771 |
| 28-day dosing schedule: Week 16: Serotype 54 | 1.733 ± 0.6598 |
| 28-day dosing schedule: Week 16: Serotype 56 | 2.750 ± 6.7280 |
| 28-day dosing schedule: Week 16: Serotype 57 | 5.422 ± 10.7795 |
| 28-day dosing schedule: Week 16: Serotype 68 | 0.728 ± 0.4390 |
| 28-day dosing schedule: Week 16: Serotype 70 | 1.350 ± 0.9931 |
| 28-day dosing schedule: Week 16: Serotype 8 | 1.294 ± 0.6476 |
| 28-day dosing schedule: Week 16: Serotype 9 | 0.517 ± 0.2550 |
| 21-day dosing schedule: Week 18 : Serotype 1 | 5.400 ± 6.4211 |
| 21-day dosing schedule: Week 18 : Serotype 12 | 0.440 ± 0.1817 |
| 21-day dosing schedule: Week 18 : Serotype 14 | 5.880 ± 4.0084 |
| 21-day dosing schedule: Week 18 : Serotype 17 | 3.700 ± 3.3978 |
| 21-day dosing schedule: Week 18 : Serotype 19 | 2.940 ± 1.3107 |
| 21-day dosing schedule: Week 18 : Serotype 2 | 3.600 ± 3.6159 |
| 21-day dosing schedule: Week 18 : Serotype 20 | 3.120 ± 1.8992 |
| 21-day dosing schedule: Week 18 : Serotype 22 | 2.520 ± 3.6486 |
| 21-day dosing schedule: Week 18 : Serotype 23 | 1.200 ± 0.8660 |
| 21-day dosing schedule: Week 18: Serotype 26 | 1.740 ± 1.9191 |
| 21-day dosing schedule: Week 18: Serotype 3 | 5.920 ± 8.6126 |
| 21-day dosing schedule: Week 18: Serotype 34 | 3.220 ± 5.0226 |
| 21-day dosing schedule: Week 18: Serotype 4 | 0.520 ± 0.5630 |
| 21-day dosing schedule: Week 18: Serotype 43 | 1.300 ± 0.8031 |
| 21-day dosing schedule: Week 18: Serotype 5 | 6.240 ± 9.6619 |
| 21-day dosing schedule: Week 18: Serotype 51 | 7.620 ± 10.4406 |
| 21-day dosing schedule: Week 18: Serotype 54 | 5.980 ± 8.1515 |
| 21-day dosing schedule: Week 18: Serotype 56 | 7.820 ± 12.0038 |
| 21-day dosing schedule: Week 18: Serotype 57 | 2.375 ± 0.5909 |
| 21-day dosing schedule: Week 18: Serotype 68 | 1.400 ± 1.5700 |
| 21-day dosing schedule: Week 18: Serotype 70 | 3.920 ± 5.6971 |
| 21-day dosing schedule: Week 18: Serotype 8 | 4.260 ± 4.2846 |
| 21-day dosing schedule: Week 18: Serotype 9 | 1.040 ± 0.6804 |
Tmax was obtained directly from the concentration versus time curve. The Tmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| hours | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 0.542 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 12 | 0.517 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 14 | 1.417 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 17 | 1.992 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 19 | 0.642 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 2 | 1.458 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 22 | 0.500 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 23 | 0.642 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 26 | 0.642 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 3 | 0.517 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 34 | 1.758 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 4 | 0.500 (0.48 to 24.10) |
| 28-day dosing schedule: Week 16: Serotype 43 | 1.750 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 5 | 0.642 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 51 | 0.650 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 54 | 0.642 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 56 | 1.633 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 57 | 0.642 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 68 | 0.650 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 70 | 0.500 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 8 | 0.542 (0.48 to 529.75) |
| 28-day dosing schedule: Week 16: Serotype 9 | 0.500 (0.48 to 529.75) |
| 21-day dosing schedule: Week 18 Serotype 1 | 71.250 (1.78 to 334.37) |
| 21-day dosing schedule: Week 18 Serotype 12 | 1.783 (0.50 to 334.37) |
| 21-day dosing schedule: Week 18 Serotype 14 | 70.450 (0.50 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 17 | 71.250 (1.78 to 337.30) |
| 21-day dosing schedule: Week 18: Serotype 19 | 1.967 (0.53 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 2 | 71.250 (1.78 to 337.30) |
| 21-day dosing schedule: Week 18: Serotype 20 | 2.050 (1.78 to 457.00) |
| 21-day dosing schedule: Week 18: Serotype 22 | 71.250 (1.78 to 337.30) |
| 21-day dosing schedule: Week 18: Serotype 23 | 2.050 (0.50 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 26 | 71.250 (1.78 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 3 | 71.250 (2.05 to 457.00) |
| 21-day dosing schedule: Week 18: Serotype 34 | 1.967 (0.53 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 4 | 1.783 (0.50 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 43 | 1.967 (0.53 to 457.00) |
| 21-day dosing schedule: Week 18: Serotype 5 | 71.250 (1.78 to 337.30) |
| 21-day dosing schedule: Week 18: Serotype 51 | 71.250 (0.53 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 54 | 71.250 (1.78 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 56 | 71.250 (1.78 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 57 | 70.850 (0.53 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 68 | 24.700 (0.50 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 70 | 1.967 (0.48 to 71.25) |
| 21-day dosing schedule: Week 18: Serotype 8 | 2.050 (1.78 to 334.37) |
| 21-day dosing schedule: Week 18: Serotype 9 | 70.450 (0.53 to 334.37) |
Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The Kel for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| 1/hour | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 0.0016 ± 0.00081 |
| 28-day dosing schedule: Week 16: Serotype 12 | 0.0017 ± 0.00037 |
| 28-day dosing schedule: Week 16: Serotype 14 | 0.0011 ± 0.00037 |
| 28-day dosing schedule: Week 16: Serotype 17 | 0.0014 ± 0.00069 |
| 28-day dosing schedule: Week 16: Serotype 19 | 0.0010 ± 0.00039 |
| 28-day dosing schedule: Week 16: Serotype 2 | 0.0010 ± 0.00054 |
| 28-day dosing schedule: Week 16: Serotype 20 | 0.0009 ± 0.00063 |
| 28-day dosing schedule: Week 16: Serotype 22 | 0.0015 ± 0.00082 |
| 28-day dosing schedule: Week 16: Serotype 23 | 0.0010 ± 0.00038 |
| 28-day dosing schedule: Week 16: Serotype 26 | 0.0013 ± 0.00057 |
| 28-day dosing schedule: Week 16: Serotype 3 | 0.0014 ± 0.00078 |
| 28-day dosing schedule: Week 16: Serotype 34 | 0.0013 ± 0.00068 |
| 28-day dosing schedule: Week 16: Serotype 4 | 0.0013 ± 0.00011 |
| 28-day dosing schedule: Week 16: Serotype 43 | 0.0013 ± 0.00041 |
| 28-day dosing schedule: Week 16: Serotype 5 | 0.0012 ± 0.00036 |
| 28-day dosing schedule: Week 16: Serotype 51 | 0.0012 ± 0.00072 |
| 28-day dosing schedule: Week 16: Serotype 54 | 0.0009 ± 0.00052 |
| 28-day dosing schedule: Week 16: Serotype 56 | 0.0014 ± 0.00053 |
| 28-day dosing schedule: Week 16: Serotype 57 | 0.0010 ± 0.00059 |
| 28-day dosing schedule: Week 16: Serotype 68 | 0.0012 ± 0.00051 |
| 28-day dosing schedule: Week 16: Serotype 70 | 0.0011 ± 0.00047 |
| 28-day dosing schedule: Week 16: Serotype 8 | 0.0013 ± 0.00043 |
| 28-day dosing schedule: Week 16: Serotype 9 | 0.0015 ± 0.00083 |
| 21-day dosing schedule: Week 18: Serotype 1 | 0.0009 |
| 21-day dosing schedule: Week 18: Serotype 12 | 0.0014 ± 0.00030 |
| 21-day dosing schedule: Week 18: Serotype 14 | 0.0005 |
| 21-day dosing schedule: Week 18: Serotype 17 | 0.0006 ± 0.00022 |
| 21-day dosing schedule: Week 18: Serotype 19 | 0.0018 ± 0.00183 |
| 21-day dosing schedule: Week 18: Serotype 2 | 0.0008 |
| 21-day dosing schedule: Week 18: Serotype 20 | 0.0009 |
| 21-day dosing schedule: Week 18: Serotype 22 | 0.0007 ± 0.00008 |
| 21-day dosing schedule: Week 18: Serotype 23 | 0.0009 ± 0.00017 |
| 21-day dosing schedule: Week 18: Serotype 26 | 0.0008 |
| 21-day dosing schedule: Week 18: Serotype 3 | 0.0024 |
| 21-day dosing schedule: Week 18: Serotype 34 | 0.0009 ± 0.00010 |
| 21-day dosing schedule: Week 18: Serotype 4 | 0.0016 ± 0.00094 |
| 21-day dosing schedule: Week 18: Serotype 43 | 0.0026 ± 0.00104 |
| 21-day dosing schedule: Week 18: Serotype 5 | 0.0008 |
| 21-day dosing schedule: Week 18: Serotype 51 | 0.0009 |
| 21-day dosing schedule: Week 18: Serotype 54 | 0.0009 |
| 21-day dosing schedule: Week 18: Serotype 56 | 0.0007 |
| 21-day dosing schedule: Week 18: Serotype 68 | 0.0027 |
| 21-day dosing schedule: Week 18: Serotype 70 | 0.0007 ± 0.00051 |
| 21-day dosing schedule: Week 18: Serotype 8 | 0.0011 |
| 21-day dosing schedule: Week 18: Serotype 9 | 0.0008 |
Average concentration of anti-pneumococcal capsular polysaccharide over the dosing interval (Cavg) was reported. The Cavg for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| mg/L | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 1.9274 ± 1.91218 |
| 28-day dosing schedule: Week 16: Serotype 12 | 0.7389 ± 0.97027 |
| 28-day dosing schedule: Week 16: Serotype 14 | 11.8127 ± 26.793 |
| 28-day dosing schedule: Week 16: Serotype 17 | 1.7723 ± 0.86237 |
| 28-day dosing schedule: Week 16: Serotype 19 | 3.2992 ± 1.55795 |
| 28-day dosing schedule: Week 16: Serotype 2 | 2.2719 ± 0.84758 |
| 28-day dosing schedule: Week 16: Serotype 20 | 2.6925 ± 2.27169 |
| 28-day dosing schedule: Week 16: Serotype 22 | 1.1703 ± 1.14923 |
| 28-day dosing schedule: Week 16: Serotype 23 | 1.8608 ± 2.37096 |
| 28-day dosing schedule: Week 16: Serotype 26 | 1.4473 ± 1.09160 |
| 28-day dosing schedule: Week 16: Serotype 3 | 1.4018 ± 0.57076 |
| 28-day dosing schedule: Week 16: Serotype 34 | 1.4310 ± 0.67369 |
| 28-day dosing schedule: Week 16: Serotype 4 | 0.3715 ± 0.13038 |
| 28-day dosing schedule: Week 16: Serotype 43 | 1.3909 ± 0.75449 |
| 28-day dosing schedule: Week 16: Serotype 5 | 2.2704 ± 0.91895 |
| 28-day dosing schedule: Week 16: Serotype 51 | 1.9760 ± 0.45341 |
| 28-day dosing schedule: Week 16: Serotype 54 | 2.4786 ± 0.70417 |
| 28-day dosing schedule: Week 16: Serotype 56 | 3.6552 ± 8.34613 |
| 28-day dosing schedule: Week 16: Serotype 57 | 7.7851 ± 14.9518 |
| 28-day dosing schedule: Week 16: Serotype 68 | 1.0037 ± 0.43741 |
| 28-day dosing schedule: Week 16: Serotype 70 | 1.8656 ± 1.16519 |
| 28-day dosing schedule: Week 16: Serotype 8 | 1.6553 ± 0.54282 |
| 28-day dosing schedule: Week 16: Serotype 9 | 0.8174 ± 0.30539 |
| 21-day dosing schedule: Week 18: Serotype 1 | 6.8000 ± 8.72068 |
| 21-day dosing schedule: Week 18: Serotype 12 | 0.6759 ± 0.07969 |
| 21-day dosing schedule: Week 18: Serotype 14 | 8.3407 ± 4.11626 |
| 21-day dosing schedule: Week 18: Serotype 17 | 3.3332 ± 2.49783 |
| 21-day dosing schedule: Week 18: Serotype 19 | 4.1177 ± 1.24514 |
| 21-day dosing schedule: Week 18: Serotype 2 | 3.1566 ± 1.78858 |
| 21-day dosing schedule: Week 18: Serotype 20 | 4.0521 ± 2.44372 |
| 21-day dosing schedule: Week 18: Serotype 22 | 1.3653 ± 0.45325 |
| 21-day dosing schedule: Week 18: Serotype 23 | 1.6720 ± 0.80975 |
| 21-day dosing schedule: Week 18: Serotype 26 | 2.5183 ± 2.29821 |
| 21-day dosing schedule: Week 18: Serotype 3 | 9.6039 ± 13.55999 |
| 21-day dosing schedule: Week 18: Serotype 34 | 1.4352 ± 0.21030 |
| 21-day dosing schedule: Week 18: Serotype 4 | 0.7559 ± 0.61634 |
| 21-day dosing schedule: Week 18: Serotype 43 | 1.9271 ± 0.61773 |
| 21-day dosing schedule: Week 18: Serotype 5 | 3.0491 ± 0.47615 |
| 21-day dosing schedule: Week 18: Serotype 51 | 11.8744 ± 15.99966 |
| 21-day dosing schedule: Week 18: Serotype 54 | 8.7747 ± 10.40792 |
| 21-day dosing schedule: Week 18: Serotype 56 | 13.4544 ± 19.77749 |
| 21-day dosing schedule: Week 18: Serotype 57 | 3.7348 ± 0.38721 |
| 21-day dosing schedule: Week 18: Serotype 68 | 1.8682 ± 1.69358 |
| 21-day dosing schedule: Week 18: Serotype 70 | 2.0323 ± 0.31507 |
| 21-day dosing schedule: Week 18: Serotype 8 | 4.2572 ± 3.86929 |
| 21-day dosing schedule: Week 18: Serotype 9 | 1.5159 ± 0.65747 |
The peak trough fluctuation within complete dosing interval at steady state of anti-pneumococcal capsular polysaccharide was reported. The peak trough fluctuation for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.
| percent fluctuation | Kedrion IVIG 10% |
|---|---|
| 28-day dosing schedule: Week 16: Serotype 1 | 128.3177 ± 62.60668 |
| 28-day dosing schedule: Week 16: Serotype 12 | 125.2166 ± 64.54247 |
| 28-day dosing schedule: Week 16: Serotype 14 | 107.5731 ± 40.60933 |
| 28-day dosing schedule: Week 16: Serotype 17 | 103.6118 ± 35.89546 |
| 28-day dosing schedule: Week 16: Serotype 19 | 110.9054 ± 50.44522 |
| 28-day dosing schedule: Week 16: Serotype 2 | 105.2306 ± 55.00248 |
| 28-day dosing schedule: Week 16: Serotype 20 | 114.6004 ± 41.03380 |
| 28-day dosing schedule: Week 16: Serotype 22 | 128.1639 ± 58.30342 |
| 28-day dosing schedule: Week 16: Serotype 23 | 116.7754 ± 45.77432 |
| 28-day dosing schedule: Week 16: Serotype 26 | 122.7546 ± 65.89653 |
| 28-day dosing schedule: Week 16: Serotype 3 | 139.1737 ± 50.45738 |
| 28-day dosing schedule: Week 16: Serotype 34 | 112.0465 ± 48.26345 |
| 28-day dosing schedule: Week 16: Serotype 4 | 117.2909 ± 65.62829 |
| 28-day dosing schedule: Week 16: Serotype 43 | 125.0358 ± 49.91946 |
| 28-day dosing schedule: Week 16: Serotype 5 | 124.7428 ± 49.15063 |
| 28-day dosing schedule: Week 16: Serotype 51 | 110.9231 ± 48.65621 |
| 28-day dosing schedule: Week 16: Serotype 54 | 123.3022 ± 53.42626 |
| 28-day dosing schedule: Week 16: Serotype 56 | 116.6480 ± 52.81535 |
| 28-day dosing schedule: Week 16: Serotype 57 | 111.5242 ± 42.65179 |
| 28-day dosing schedule: Week 16: Serotype 68 | 114.0701 ± 58.01418 |
| 28-day dosing schedule: Week 16: Serotype 70 | 109.4081 ± 43.80010 |
| 28-day dosing schedule: Week 16: Serotype 8 | 117.3221 ± 38.97972 |
| 28-day dosing schedule: Week 16: Serotype 9 | 130.6095 ± 65.79680 |
| 21-day dosing schedule: Week 18: Serotype 1 | 81.4603 ± 40.27141 |
| 21-day dosing schedule: Week 18: Serotype 12 | 102.9813 ± 10.00904 |
| 21-day dosing schedule: Week 18: Serotype 14 | 73.9639 ± 29.28795 |
| 21-day dosing schedule: Week 18: Serotype 17 | 76.0492 ± 42.17688 |
| 21-day dosing schedule: Week 18: Serotype 19 | 94.4390 ± 30.99072 |
| 21-day dosing schedule: Week 18: Serotype 2 | 80.1377 ± 36.22955 |
| 21-day dosing schedule: Week 18: Serotype 20 | 83.5202 ± 42.23144 |
| 21-day dosing schedule: Week 18: Serotype 22 | 91.9216 ± 20.16314 |
| 21-day dosing schedule: Week 18: Serotype 23 | 84.5653 ± 31.15550 |
| 21-day dosing schedule: Week 18: Serotype 26 | 88.7836 ± 30.46916 |
| 21-day dosing schedule: Week 18: Serotype 3 | 90.4017 ± 39.81294 |
| 21-day dosing schedule: Week 18: Serotype 34 | 91.6269 ± 16.96157 |
| 21-day dosing schedule: Week 18: Serotype 4 | 79.5022 ± 41.16158 |
| 21-day dosing schedule: Week 18: Serotype 43 | 81.6962 ± 28.91186 |
| 21-day dosing schedule: Week 18: Serotype 5 | 88.6356 ± 17.56577 |
| 21-day dosing schedule: Week 18: Serotype 51 | 71.0749 ± 31.74626 |
| 21-day dosing schedule: Week 18: Serotype 54 | 72.7200 ± 31.26330 |
| 21-day dosing schedule: Week 18: Serotype 56 | 82.4508 ± 27.11113 |
| 21-day dosing schedule: Week 18: Serotype 57 | 98.1611 ± 9.69314 |
| 21-day dosing schedule: Week 18: Serotype 68 | 82.9015 ± 37.95746 |
| 21-day dosing schedule: Week 18: Serotype 70 | 91.3286 ± 19.12896 |
| 21-day dosing schedule: Week 18: Serotype 8 | 65.5637 ± 36.02827 |
| 21-day dosing schedule: Week 18: Serotype 9 | 75.8333 ± 30.77330 |
Collected over Up to study termination visit (Week 52). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Kedrion IVIG 10% | 0/47 (0%) | 4/47 (8.5%) | 38/47 (80.9%) |
| Event | Kedrion IVIG 10% |
|---|---|
| Cholecystitis acuteHepatobiliary disorders | 1/47 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/47 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/47 |
| DepressionPsychiatric disorders | 1/47 |
| HypotensionVascular disorders | 1/47 |
| Event | Kedrion IVIG 10% |
|---|---|
| HeadacheNervous system disorders | 19/47 |
| FatigueGeneral disorders | 12/47 |
| NauseaGastrointestinal disorders | 11/47 |
| SinusitisNervous system disorders | 11/47 |
| upper respiratory tract infectionInfections and infestations | 8/47 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/47 |
| DiarrhoeaGastrointestinal disorders | 7/47 |
| PyrexiaGeneral disorders | 6/47 |
| Coombs direct test positiveInvestigations | 6/47 |
| DepressionPsychiatric disorders | 6/47 |
The Full Analysis Set (FAS) included all participants who had received at least 1 dose of study medication.
| Age, Continuous(years) | Kedrion IVIG 10% |
|---|---|
| Mean | 52.6 ± 12.90 |
| Sex: Female, Male(Participants) | Kedrion IVIG 10% |
|---|---|
| Female | 30 |
| Male | 17 |
| Ethnicity (NIH/OMB)(Participants) | Kedrion IVIG 10% |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 44 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Kedrion IVIG 10% |
|---|---|
| White | 45 |
| Mexican | 1 |
| White and African American | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Dec 2020, 19 months.
Results were first posted in Jan 2022, 1 year 1 month after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Primary Immunodeficiency Diseases →
Kedrion S.p.A.